Johnson & Johnson (J&J) has completed the acquisition of Actelion Pharmaceuticals for approximately $30bn in an all-cash transaction through its Swiss subsidiary Janssen Holding.

The European Commission has approved the acquisition, which was notified on 12 April, under the EU merger regulation on 9 June.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The deal is expected to expand Janssen’s portfolio with Actelion PAH franchise’s differentiated in-market medicines and late-stage therapies such as Opsumit, Uptravi and Tracleer.

According to J&J Pharmaceuticals executive vice-president and worldwide chairman Joaquin Duato, the transaction establishes a sixth therapeutic area for the company, aiding in the bolster of medical innovation for serious illnesses and unmet medical needs.

“Adding Actelion to our already strong pharmaceutical business expands our portfolio with leading, differentiated in-market medicines and promising late-stage products.”

J&J chairman and CEO Alex Gorsky said: “We are very pleased to complete this compelling transaction and look forward to the value it will create for Johnson & Johnson and for patients around the world suffering from pulmonary arterial hypertension (PAH) and other serious illnesses.

“Adding Actelion to our already strong pharmaceutical business expands our portfolio with leading, differentiated in-market medicines and promising late-stage products.”

Actelion has divested, in connection with the completion of the transaction, its discovery operations and early stage clinical development assets to new Swiss biopharmaceutical firm Idorsia.

J&J will hold 9.9% of the shares in Idorsia through one of its subsidiaries.

The firm further exercises a right to an additional 22.1% of Idorsia’s outstanding equity and option on an investigational product ACT-132577 currently being developed for resistant hypertension.